(vianews) - genomic vision (gv.pa) experienced an extraordinary increase of 28.21% over 10 sessions, following three consecutive days of losses. even as cac 40 fell by 1.32% overall to eur7,089.83; its closing price for genomic vision stood out as significantly below its 52-week high of eur0.10 and thus representing a substantial decline from its former highs.
about genomic vision
genomic vision societe anonyme is a french molecular diagnostics and technology company specializing in single dna detection tools for research applications as well as in vitro diagnostics. fibervision provides a molecular combing platform, fibercomb is a molecular combing system and fiberstudio software is used for dna extraction kit preparation as well as accessories. they also have fiberprobes specifically tailored to brca or hereditary nonpolyposis colorectal cancer genomic morse code sets for analysis. genomic vision offers combing services for gene editing event validation, incorrect event detection and off-target/on-target ratio quantification. they have formed strategic alliances with quest diagnostics, la timone hospital and institut pasteur; founded in 2004 and located in bagneux france.
yearly analysis
based on available data, genomic vision's stock is currently trading at eur0.01, significantly below its 52-week high of eur0.10 but higher than its 52-week low of eur0.01 which indicates it has experienced significant value loss since march. genomic vision anticipates negative 6.6% sales growth for this year; therefore, revenue may decrease; however, next year it anticipates 100% revenue growth, suggesting significant expansion of its business. overall, investors should exercise extreme caution before investing in genomic vision due to its current stock price being significantly below its 52-week high and revenue expected to decline this year. with its predicted 100% sales growth next year however, investors willing to take on higher risk should explore this stock further before making any definitive investment decisions. to do this successfully.
technical analysis
genomic vision, a biotechnology company specializing in cancer diagnostics and personalized medicine development, has experienced dramatic fluctuations in its stock prices. at present, its share price is fluctuating above its 50-day moving average of eur0.01, an indication of short-term bullishness; yet far below its 200-day moving average of eur0.02 which signals long-term bearish sentiment. according to its trading volume, genomic vision's latest reported volume was 86.07% lower than its average trading volume of 5741760 - suggesting traders may have lost interest in its stock. looking at genomic vision's volatility, its intraday variation average for the past week, month and quarter was negative 5.59%; these values decreased to negative 2.68% during each quarter and quarter respectively with highest amplitude being reached during last week with 7.066%; last month it reached 3.744% before reaching its highest average volatility level during quarter. according to the stochastic oscillator, genomic vision's stock is currently considered overbought (>=80), signaling that it may be time for a correction. conclusion: in general, genomic vision's stock price is currently experiencing short-term bullishness but long-term bearishness. with declining trading volume and overbought status indicating that caution should be used when investing in this stock. investors should monitor its performance closely before taking profits or reducing positions as needed.
quarter analysis
data shows that this company has experienced only modest revenue growth. their year-on-year quarterly growth of 3.8% indicates an increase in revenues compared to the same quarter last year; however, their total twelve trailing month revenue figure of 1.48m suggests their revenues have not experienced significant increases over time. investors should assess a company's revenue growth alongside other financial metrics like net income, cash flow and balance sheet health to gain a holistic picture of its financial performance. furthermore, industry and macro-economic conditions should also be taken into consideration to see if its revenue growth indicates healthy and sustainable businesses.
equity analysis
according to available data, genomic vision currently has an eps of eur-0.1 for its trailing twelve month earnings per share, suggesting it is currently not producing profits and that investors may be reluctant to invest in its stock. furthermore, the company's return on equity (roe) for the twelve trailing months stands at an alarming negative 762.49% - indicating it does not generate profit relative to shareholder contributions, making for a concerning sign for investors. given genomic vision's negative eps and roe figures, investors should proceed with caution when making an investment decision in genomic vision. conduct thorough research on its financial performance, management capabilities and growth prospects before reaching your final decision to invest.
more news about genomic vision (gv.pa).